These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38066089)

  • 21. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
    Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
    Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population.
    Chen BF; Tsai YF; Chao TC; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Lai JI; Tseng LM; Huang CC
    Clin Exp Med; 2024 Aug; 24(1):185. PubMed ID: 39133334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
    Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
    Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
    Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
    Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
    Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer.
    Gomes I; Gallego-Paez LM; Jiménez M; Santamaria PG; Mansinho A; Sousa R; Abreu C; Suárez EG; Costa L; Casimiro S
    Cell Rep Med; 2023 Aug; 4(8):101120. PubMed ID: 37451269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
    Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
    Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
    Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
    O'Sullivan CC; Clarke R; Goetz MP; Robertson J
    JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
    Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U
    Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
    Chew SM; Ferraro E; Safonov A; Chen Y; Kelly D; Razavi P; Robson M; Seidman AD
    Eur J Cancer; 2024 Aug; 207():114175. PubMed ID: 38896996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
    Martin JM; Handorf EA; Montero AJ; Goldstein LJ
    Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
    Adamia S; Bhatt S; Wen K; Chyra Z; Fell GG; Tai YT; Pioso MS; Abiatari I; Letai A; Dorfman DM; Hideshima T; Anderson KC
    Leukemia; 2022 Apr; 36(4):1088-1101. PubMed ID: 35082402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
    Yoshida A; Lee EK; Diehl JA
    Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
    Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
    Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
    Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
    Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
    Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
    Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification.
    Shi C; Ju H; Zhou R; Xu S; Wu Y; Gu Z; Wang Y; Chen W; Huang X; Han Y; Sun S; Li C; Wang M; Zhou G; Zhang Z; Li J; Ren G
    BMC Med; 2024 May; 22(1):215. PubMed ID: 38807144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.